Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.


NDAQ:LEXX - Post by User

Bullboard Posts
Comment by LANNY9on Sep 17, 2019 6:54pm
92 Views
Post# 30137815

RE:RE:RE:Sure looks like a 'financing' is being planned...

RE:RE:RE:Sure looks like a 'financing' is being planned...I'm not expecting much for sales until 2020 but there is oppurtuntiy in the States through the licencing agreements as well as a small amount from their ChrgD and TruboCBD products. How much is anyone's guess however. It will take a few years for this stock to present it's true value imo.

The nicotine aspect of the business can be big, even with the lawsuits Juul is facing. I can't speak to their marketing and if in fact they target kids but supsect it could be difficult to prove? But only need one judge right?

As to the deaths in the States, from what I understand it is the products mixed with flavor oils, vitamin E and glycols that are thought to be the culprit(s) when vaped. But they aren't sure yet of course and are mentioning THC products. The oils are mixed with other chemicals, flavor enhancers etc. 

That said, I do think LXX products have proven safe to date. The products are consumed, not vaped which is a giant step forward not only in safety measures but convenience to user.

Phamaceuticals and suplplements though could be the biggest part of the business in the future if everythign continues to prove itself out.
Bullboard Posts